Viekira Pak​​

Kathryn Dzintars, Pharm.D., BCPS
Viekira Pak​​ is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Viekira Pak: combination pack of four medications.
    • Ombitasvir/paritaprevir/ritonavir and dasabuvir
    • Indicated for treatment of hepatitis C virus (HCV) genotype 1 (1a or 1b) infection with or without the addition of ribavirin
  • Viekira Pak has been studied in patients with HIV co-infection, liver transplant recipients and those with compensated cirrhosis and/or mild hepatic impairment

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Viekira Pak: combination pack of four medications.
    • Ombitasvir/paritaprevir/ritonavir and dasabuvir
    • Indicated for treatment of hepatitis C virus (HCV) genotype 1 (1a or 1b) infection with or without the addition of ribavirin
  • Viekira Pak has been studied in patients with HIV co-infection, liver transplant recipients and those with compensated cirrhosis and/or mild hepatic impairment

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: March 2, 2017